Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Ani Pharmaceuticals (ANIP) Capital Expenditures (2016 - 2026)

Ani Pharmaceuticals' Capital Expenditures history spans 16 years, with the latest figure at -$11.5 million for Q4 2025.

On a quarterly basis, Capital Expenditures rose 13.31% to -$11.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 98.49% increase, with the full-year FY2025 number at $1.0 million, up 98.49% from a year prior.
Capital Expenditures hit -$11.5 million in Q4 2025 for Ani Pharmaceuticals, down from $6.1 million in the prior quarter.
Over the last five years, Capital Expenditures for ANIP hit a ceiling of $12.2 million in Q3 2024 and a floor of -$13.3 million in Q4 2024.
Historically, Capital Expenditures has averaged $245800.0 across 5 years, with a median of $612000.0 in 2021.
Biggest five-year swings in Capital Expenditures: soared 3258.06% in 2021 and later plummeted 2624.6% in 2023.
Tracing ANIP's Capital Expenditures over 5 years: stood at $356000.0 in 2021, then plummeted by 30.34% to $248000.0 in 2022, then plummeted by 2624.6% to -$6.3 million in 2023, then tumbled by 112.63% to -$13.3 million in 2024, then increased by 13.31% to -$11.5 million in 2025.
Business Quant data shows Capital Expenditures for ANIP at -$11.5 million in Q4 2025, $6.1 million in Q3 2025, and $4.0 million in Q2 2025.